

Carolyn Rutherford

**M.B.A., Grad. Dip. Epidemiology and Biostatistics,
B. Pharmacy, Cert. Health Economics**

OVERVIEW

Carolyn is a health economist and pharmacist, with over 20 years' experience in the pharmaceutical industry in varied market access and health economics roles at KMC Health Care, CSL, GlaxoSmithKline and Glaxo Wellcome Australia. Her experience includes many years of developing and implementing market access strategies for new chemical entities and for new and revised PBS listings. This is complemented by her clinical understanding and experience in hospital and retail pharmacy, as well as practical experience with dispensing via the PBS.

At GlaxoSmithKline and Glaxo Wellcome Australia she managed a team of health economists and market access specialists. Key responsibilities included the development of product reimbursement, pricing strategy development, involvement with cross-company product development teams, liaising with key Pharmaceutical Benefits Branch personnel and opinion leaders and staff and budget management. Achievements included the successful PBS listing of a number of key products, the development of pricing and price protection strategies and developing strong relationships with government and industry personnel.

At KMC Health Care she has worked across a wide range of therapeutic areas including pain management, specialist hospital products, diabetes, respiratory, gastrointestinal, HIV and infectious diseases, epilepsy, anti-depressants, nutritional products, dermatology and medical devices. Successfully completed projects include numerous PBAC submissions, hospital formulary submissions, pricing submissions, market access strategies for new products and medical device reimbursement submissions.

Carolyn has particularly well-developed medical and persuasive writing skills, the ability to analyse and concisely report complex clinical and economic data and well developed personal communication skills. She is very reliable, organized and time-efficient, with advanced project management skills.

CURRENT APPOINTMENTS

- 2004 - Senior Health Economist**
KMC Health Care, Australia
- 1990 - Pharmacist – Community/Hospital Environment**
Various Pharmacies, Melbourne, Australia

QUALIFICATIONS

Postgraduate

Graduate Diploma of Epidemiology and Biostatistics
The University of Melbourne, Melbourne, Vic

Certificate of Health Economics
Monash University, Melbourne

Masters of Business Administration (MBA)
Deakin University, Victoria Australia

Undergraduate

Bachelor of Pharmacy
Victorian College of Pharmacy, Monash University, Melbourne

PREVIOUS APPOINTMENTS

- 2002 – 2003** **Epidemiologist**
CSL
- 1996 - 2002** **Health Outcomes Manager**
GlaxoSmithKline/Glaxo Wellcome Australia
- 1995 - 1996** **Medical Affairs Associate**
GlaxoSmithKline/Glaxo Wellcome Australia

MEMBERSHIPS/ASSOCIATION INVOLVEMENT

- Pharmacy Board (Victoria) - Registered Pharmacist
- Pharmaceutical Society of Australia - Current member
- ARCS Australia - Current member

PUBLICATIONS/CONFERENCE PRESENTATIONS

- Ian Gordon, Carolyn Rutherford, Kelly Makarounas-Kirchmann, Matt Kirchmann. "Meta-analysis of average change in laboratory-measured HbA1c among people with type 1 diabetes mellitus using the 14 day Flash Glucose Monitoring System". Diabetes Research and Clinical Practice 164 (2020): 108158.
- Couchman M, Nunn A, Delaney D, Thavaseelan J Bennett N, Rutherford C, Kirchman M. Cost-effectiveness of long-term intermittent catheterisation with hydrophilic and uncoated catheters in traumatic spinal cord injury in Australia. International Continence Society 49th Annual Meeting, Gothenburg, Sweden, September 2019. Published in Neurourology & Urodynamics 2019:38(S3):Abstract 271.
- Carolyn Rutherford, Rose Mills, Peter Gibson, Martin Price. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003; 8(3): 371-5.
- Christine Jenkins, Janet Wilson, Carolyn Rutherford, Andrew Perry, Phillip Whitehead. Asthma management costs are lower with combination fluticasone/salmeterol (250/50 mcg bd) in a single inhaler than with

budesonide 800mcg bd plus eformoterol 12mcg bd via separate inhalers. Poster presented at Thoracic Society of Australia and New Zealand (TSANZ) conference, Cairns, 2002.

Pratt NL, Beilby JJ, Marley JE, Walker DC, Duszynski KM, Rutherford, C and McManus P. Descriptive epidemiological study of doctor prescribing for asthma therapy in Australia. *Pharmacoepidemiol Drug Saf.* 2001; 10(S1): S81.

Christine McDonald, Carolyn Rutherford. Cost-effectiveness of inhaled combination salmeterol/fluticasone compared with higher dose fluticasone in Australians with asthma. Poster presented at Thoracic Society of Australia and New Zealand (TSANZ) conference, Brisbane, 2001.

John Wilson, Carolyn Rutherford. The cost-effectiveness of inhaled fluticasone propionate and budesonide in Australian adults and children with asthma. Poster presented at Thoracic Society of Australia and New Zealand (TSANZ) conference, Melbourne, 2000.

Josephine Mauskopf, Sheryl Cates, Adrian Griffin, Deirdre Neighbours, Sarah Lamb, Carolyn Rutherford. Cost-effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. *Pharmacoeconomics* 2000 Jun; 17(6): 611-620

Abstract submitted to the Australian Diabetes Society meeting, Adelaide 2002: J. Beilby, K. Duszynski, L. Hobbs and C. Rutherford. Australian general practice medical records validate published findings in the oral drug treatment of type 2 diabetes.